HIV Mutation Detail Information

> T215Y Search Result

Mutation Information

Mutation Site	T215Y
Mutation Type	Amino acid level
Gene/Protein/Region Type	RT

Literature Information

PubMed PMID	30544247
Disease	HIV infection/AIDS
Published Year	2019
Journal	The Journal of antimicrobial chemotherapy
Title	Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance.
Author	Geretti AM,White E,Orkin C,Tostevin A,Tilston P,Chadwick D,Leen C,Sabin C,Dunn DT,UK HIV Drug Resistance Database and UK CHIC Study.
Evidence	Most (203 of 269, 75.5%) had singleton TAMs, commonly a revertant of T215Y or T215F (112 of 269, 41.6%). Over a median of 2.5 years of follow-up, 834 of 6599 (12.6%) subjects experienced viraemia (HIV-1 RNA >50 copies/mL). The adjusted HR for viraemia was 2.17 with PI/b versus NNRTI-based therapy (95% CI 1.88-2.51;P < 0.001).

Contents
Description

Mutation Information Note

Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)

Literature Information Note

Evidence: sentence contains this mutation information in the citation